Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Bronchiolitis Obliterans Syndrome 1

Interventions

TIC10 compound 3trastuzumab deruxtecan 2umbralisib 1ublituximab 1pembrolizumab 1infigratinib 1enfortumab vedotin 1duvelisib 1blinatumomab 1belumosudil 1Rituximab 1KD025 1Gemcitabine 1Crizotinib 1Cisplatin 1Carboplatin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Has announcements × KD025 × Clear all
NCT03640481 2024-12-12

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Sanofi

Phase 2 Terminated
159 enrolled 25 charts 1 FDA

Bronchiolitis Obliterans Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡